An animal model is a non-human species used in biomedical research because it can mimic aspects of a biological process or disease found in humans.
Disease-to-target discovery is the process of identification and early validation of targets involved in a disease.
COVID-19 symptoms can vary widely and may include fever, cough, shortness of breath, fatigue, muscle or body aches, loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, and diarrhea. Some individuals may remain asymptomatic.
IBT Bioservices has developed an extensive assortment of reagents to facilitate the advancement of therapeutics and assay development, thus supporting the progress of research on respiratory viruses.We offers a diverse array of products and services designed to facilitate respiratory virus research, ranging from viral proteins to antiserum and antibodies.
Using advanced cellular and molecular techniques, we evaluate the antiviral activity of potential drugs and neutralizing activity of vaccines against SARS-CoV-2 and its variants. These studies help identify compounds that can effectively inhibit viral replication, reduce viral load, and prevent viral entry into host cells. We investigate the mechanism of action of potential treatments and vaccines, providing valuable insights into their ability to combat the virus and its emerging variants
Our team assists in compiling and organizing preclinical data required for regulatory submissions, helping streamline the approval process and facilitating the transition from preclinical to clinical trials.
Our experienced researchers utilize appropriate animal models, such as mice, ferrets, or nonhuman primates, to mimic SARS-CoV-2 infection and assess the safety and efficacy of potential treatments and vaccines. We closely monitor key parameters, including viral load, immune response, disease progression, lung pathology, and overall survival, to evaluate the effectiveness of the tested interventions. Our in vivo studies provide critical data on the treatment or vaccine's ability to control viral replication, reduce disease severity, and enhance host immune responses.
At IBT, we are dedicated to advancing the field of COVID-19 research and development through reliable and accurate in vitro and in vivo preclinical testing services. Our commitment to scientific excellence, ethical practices, and adherence to regulatory guidelines positions us as a trusted partner in the fight against this ongoing pandemic and its evolving variants.Contact us today to learn more about how our preclinical testing services can accelerate the development of promising treatments and vaccines for SARS-CoV-2 and its variants.
You have no billing addresses.